Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY: Lung fibrosis by any cause can be a debilitating disease. Not all current medical options are equally effective under randomized-controlled trials. Further studies with novel therapies are needed to control symptoms. The compounding presence of pulmonary hypertension will further limit the patient activity, quality of life and survival. As it has been reviewed, not all pulmonary hypertension-specific agents effectively work in these three subset groups.
|
Authors | Kamyar Afshar, Om P Sharma |
Journal | Current opinion in pulmonary medicine
(Curr Opin Pulm Med)
Vol. 14
Issue 5
Pg. 427-33
(Sep 2008)
ISSN: 1531-6971 [Electronic] United States |
PMID | 18664973
(Publication Type: Journal Article, Review)
|
Topics |
- Humans
- Hypertension, Pulmonary
(complications)
- Lung Diseases, Interstitial
(epidemiology, therapy)
- Lung Transplantation
- Pulmonary Fibrosis
(epidemiology, therapy)
- Risk Factors
- Sarcoidosis, Pulmonary
(complications)
- Scleroderma, Diffuse
(complications)
|